Loading quotes...
Forecast
The analysts' average price target is âŹ27.31 (+66.73%). The median is âŹ29.99 (+83.09%).
| Buy |
Â
25 |
| Hold |
Â
11 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Acadia Pharmaceuticals: US court preliminarily approves settlement in shareholder derivative suit
A US district court in California gave preliminary approval to the settlement in the shareholder derivative suit Kanner et al. v. Biggar et al. on August 24, 2026. Acadia must publish the court documents notifying shareholders of the settlement; details are available in the exhibits to the SEC filing. Acadiaâs operations remain stable, the stock is trading at $27.83, and analyst ratings as well as recent approvals and clinical progress support a positive outlook. » More on de.investing.com
Acadia Pharmaceuticals puts growth and remlifanserin pipeline at center of conference
At the Canaccord conference Acadia Pharmaceuticals highlighted strong commercial momentum for NUPLAZID (annualized revenue run rate of $700 million) and DAYBUE, whose STIX formulation is rapidly gaining market share. The company expects Phase II/III data for remlifanserin in Alzheimerâs psychosis in September/October 2024, seen as an important catalyst. Acadia has roughly $1 billion in cash, plans to launch DAYBUE in Europe after a positive CHMP opinion, and remains open to selective acquisitions. Management cited awareness building, commercial discipline and regulatory uncertainty as key factors for further growth. » More on de.investing.com
Acadia Pharmaceuticals stock reaches 52-week high after strong Q2 results
Acadia Pharmaceuticals shares rose to a 52-week high of around $29.77 and gained 36% over the past six months (YTD +18.23%). For Q2 2026 the company reported revenue of about $308 million, beating the $296 million consensus, driven by strong Daybue sales ($125 million) and stable Nuplazid revenue. Several analysts then raised their price targets (e.g., RBC USD 37, Oppenheimer USD 25, Citizens USD 36) and H.C. Wainwright reiterated a buy recommendation, citing progress in the phaseâ2 RADIANT study. InvestingPro rates the stock as undervalued, and the company raised its 2026 guidance, supporting the positive outlook. » More on de.investing.com
FDA grants Acadia fast-track status for Alzheimer's drug remlifanserin
The FDA has granted fast-track status to Acadiaâs compound remlifanserin for the treatment of hallucinations and delusions in Alzheimerâs psychosis. Acadia has completed patient recruitment for the Phase 2 portion of the RADIANT program and expects topline results in SeptemberâOctober 2026; Phase 3 screening and recruitment are already underway. Remlifanserin is an inverse agonist at the 5-HT2A receptor intended to avoid direct dopamine blockade and related safety issues. » More on de.investing.com
Acadia Pharmaceuticals insider sells nearly half of direct holdings
James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, sold 11,421 shares in an open-market transaction on June 26, 2026âabout 46.6% of his direct holdingsâat a weighted average price of $26.08, leaving him with 13,088 shares. The sale, executed under a pre-established Rule 10b5-1 plan, was his largest single open-market disposition and coincided with a share rally after an EMA recommendation for Daybue. Company fundamentals remain strong, with Q1 2026 revenue of $268.1 million and ongoing late-stage pipeline programs. The filings show no derivative or indirect holdings were involved, and recent larger sales reflect reduced available capacity rather than disclosed discretionary changes in strategy. » More on finance.yahoo.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 302.19m | 27.28% |
| Gross profit | 271.21m | 23.85% |
| Net profit | 47.25m | 22.74% |
| EBITDA | 71.02m | 75.28% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | âŹ2.94bn |
Number of shares | 172.83m |
52-week high/low | âŹ28.13 - âŹ14.41 |
| Dividends | No |
Beta | 0.89 |
P/E ratio | 8.80 |
PEG ratio | 0.24 |
P/B ratio | 2.33 |
P/S ratio | 2.70 |
Company profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
| Name | Acadia Pharmaceuticals |
| CEO | Catherine E. Owen Adams |
| Headquarters | San Diego,
ca USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 27/05/2004 |
| Employees | 797 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ACAD |
Frankfurt | DR6.F |
DĂŒsseldorf | DR6.DU |
London | 0A4W.L |
SIX | DR6.SW |
MĂŒnchen | DR6.MU |